MedTrace Logo

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

NCT05981235 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-07-31

No results posted yet for this study

Summary

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

Conditions

  • Gastrointestinal Tumors

Interventions

BIOLOGICAL

AZD6422 CLDN18.2 CAR-T product

AZD6422 CAR-T product infusion after pre-conditioning

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Peking University

    lead OTHER

Principal Investigators

  • Lin Shen, PHD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-14
Primary Completion
2025-06-25
Completion
2025-06-25

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05981235 on ClinicalTrials.gov